Form 8-K VERU INC. For: Jun 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Why BofA says July Fed rate hike would be "unprecedented"
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Veru partners with Novo Nordisk for obesity drug combination study
June 4, 2026 8:42 AM EDTVeru Inc. (NASDAQ: VERU) entered into a clinical supply agreement with Novo Nordisk A/S on June 2, 2026, for the company's Phase 2b PLATEAU clinical study.
The study will evaluate the combination of Veru's enobosarm, an oral selective androgen receptor modulator, with Novo Nordisk's... More
